Enanta Pharmaceuticals (ENTA) investor relations material

Executive summary

• Focused on developing small molecule drugs for virology and immunology, with wholly-owned programs in RSV, COVID-19, HBV, and type 2 inflammatory diseases.

• Pipeline includes clinical and preclinical candidates for RSV (zelicapavir, EDP-323), KIT, STAT6, and MRGPRX2 inhibitors for immunology indications.

• Initiated dosing in LOTUS, a Phase 2b pediatric trial of zelicapavir for RSV, and on track to start RESOLVE, a registrational Phase 2b/3 trial in high-risk adults; topline data expected in 2027.

• Advancing immunology pipeline with EDP-978 (KIT inhibitor) and EPS-3903 (STAT6 inhibitor); IND filing for EPS-3903 and candidate selection for MRGPRX2 expected in 2H 2026.

• Royalty revenue is derived from AbbVie's sales of MAVYRET/MAVIRET for HCV, with a royalty sale agreement in place with OMERS for a portion of future royalties.

Financial highlights

• Revenue for the quarter ended June 30, 2026 was $14.4 million, down from $18.3 million year-over-year, due to lower HCV sales by AbbVie.

• Net loss for the quarter was $19.5 million ($0.67 per share), compared to $18.3 million ($0.85 per share) in the prior year.

• Research and development expenses decreased by $5.1 million for the quarter, mainly due to timing of RSV clinical trials.

• General and administrative expenses decreased by $0.5 million for the quarter, reflecting lower stock-based compensation and legal expenses.

• Cash, cash equivalents, and marketable securities totaled $211.5 million as of June 30, 2026.

Outlook and guidance

• Existing cash and retained HCV royalty streams are expected to fund operations into fiscal 2029.

• Topline data from LOTUS (pediatric RSV) and RESOLVE (high-risk adult RSV) trials expected in 2027.

• Anticipates increased R&D expenses in the next 12 months due to new and ongoing clinical trials, especially in RSV.

• Topline Phase 1 data for EDP-978 expected in 4Q 2026; IND filing for EPS-3903 and MRGPRX2 candidate selection targeted for 2H 2026.

• Plans to initiate a registrational Phase 2b/3 trial for zelicapavir in high-risk adults and a Phase 2b pediatric trial, with data expected in 2027.